VcMMAE is widely used in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. It serves as a potent payload that is linked to specific antibodies designed to recognize and bind to cancer cells. Once the antibody attaches to the target cell, VcMMAE is internalized and released, exerting its cytotoxic effects by disrupting microtubule function, leading to cell cycle arrest and apoptosis. This targeted approach minimizes damage to healthy cells, making it a valuable component in treating various cancers, including lymphoma, breast cancer, and leukemia. Its application is particularly significant in enhancing the efficacy and reducing the side effects of chemotherapy.